(WINT)

Role: 10%+ Owner
Signature: /s/ Lin, Jung-Chin
Issuer symbol: WINT
Transactions as of: 20 May 2020
Net transactions value: +$2,382,538
Form type: 4
Filing time: 10 Jan 2022, 16:03:57 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	WINT	Common Stock	Other	$0	-3,551,750	-75%	$0.000000	1,183,916	20 May 2020	By Bioengine Capital Inc.	F1, F2
transaction	WINT	Common Stock	Purchase	$399,997	+55,172	+4.7%	$7.25	1,239,088	20 May 2020	By Bioengine Capital Inc.	F2
transaction	WINT	Common Stock	Purchase	$1,982,541	+1,239,088		$1.60	1,239,088	30 Dec 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	WINT	SERIES F WARRANTS	Other	$0	0		$0.000000^*	0	24 Jun 2020	Common Stock	384,824	$3.68	By Bioengine Capital Inc.	F4
transaction	WINT	SERIES G WARRANTS	Other	$0	-249,004	-50%	$0.000000	249,004	20 May 2020	Common Stock	249,004	$12.15	By Bioengine Capital Inc.	F5, F6, F7
transaction	WINT	SERIES J WARRANTS	Purchase	$0	+55,172		$0.000000	55,172	20 May 2020	Common Stock	55,172	$7.80	By Bioengine Capital Inc.	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Center Laboratories, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The Reporting Person voluntarily discloses that, on May 20, 2020, the Issuer effected a 1-for-3 reverse stock split of its Common Stock (the "Reverse Stock Split"), which resulted in the Reporting Person's beneficial ownership of issued and outstanding Common Stock being reduced from 3,551,750 shares of Common Stock to 1,183,916 shares of Common Stock. The shares of Common Stock are directly held by Bioengine Capital Inc., and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc.
F2	The shares of Common Stock are directly held by Bioengine Capital Inc, and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc.
F3	On December 30, 2021, the Reporting Person purchased all remaining shares of Common Stock held by Bioengine Capital Inc., and now holds the shares directly.
F4	The Reporting Person voluntarily discloses that, on July 24, 2020, Series F Warrants had expired. The Series F Warrants were directly held by Bioengine Capital Inc. and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc. As a result, the Reporting Person currently indirectly owns 0 shares of Series F Warrants.
F5	The Reporting Person voluntarily discloses that, on May 20, 2020, in connection with the Reverse Stock Split, the Issuer effected a 1-for-3 reverse split of all of its issued and outstanding Series G Warrants, which resulted in the Reporting Person's beneficial ownership of Series G Warrants being reduced from 747,012 shares of Series G Warrants to 249,004 shares of Series G Warrants.
F6	The Series G and Series J Warrants are directly held by Bioengine Capital Inc. and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc.
F7	The exercise of the Series G Warrants is subject to a beneficial ownership limitation of 9.99%, and this limitation can only be changed with effect from the 61st day after a notice requesting such change is delivered to the Issuer.

Remarks:

This filing constitutes a Form 4 exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended, as a result of the transactions reported herein.